Retinal ischemia results in the loss of vision in a number of ocular diseases including acute glaucoma, diabetic retinopathy, hypertensive retinopathy and retinal vascular occlusion. Recent studies have shown that most of the neuronal death that leads to loss of vision results from apoptosis. XIAPmediated gene therapy has been shown to protect a number of neuronal types from apoptosis but has never been assessed in retinal neurons following ischemic-induced cell death. We injected an adeno-associated viral vector expressing XIAP or GFP into rat eyes and 6 weeks later, rendered them ischemic by raising intraocular pressure. Functional analysis revealed that XIAP-treated eyes retained larger b-wave amplitudes than GFP-treated eyes up to 4 weeks post-ischemia. The number of cells in the inner nuclear layer (INL) and the thickness of the inner retina were significantly preserved in XIAP-treated eyes compared to GFP-treated eyes. Similarly, there was no significant reduction in optic nerve axon numbers in XIAP-treated eyes. There were also significantly fewer TUNEL (TdT-dUTP terminal nick end labeling) positive cells in the INL of XIAP-treated retinas at 24 h post-ischemia. Thus, XIAPmediated gene therapy imparts both functional and structural protection to the retina after a transient ischemic episode.
Introduction
Like cerebral ischemia (stroke), retinal ischemia is the result of an insufficient supply of blood to neurons due to occlusion of blood vessels. [1] [2] [3] [4] As a consequence of reduced blood supply, retinal cells undergo hypoxia causing a number of pathophysiological processes, including glutamate toxicity and free radical formation, that ultimately end in damage to retinal neurons and cell death by apoptosis. 1, [3] [4] [5] [6] [7] Current treatments aim at reestablishing retinal circulation before the damage leads to irreversible vision loss. This is attained by a combination of therapeutic regimens, including laser treatment, ocular massage, anticoagulants such as tissue plasminogen activator (t-PA), and vasodilators. These treatments have limited success however. Laser treatment must be implemented early enough to be effective, while ocular massage, anticoagulants, and vasodilators are only useful in central retinal artery occlusion (CRAO) patients when applied in combination with other treatments. 8 A number of neuroprotective agents have also been tested. These agents delay cell death in the retina after ischemia, but do not permanently rescue cells. 3, [9] [10] [11] In order to rescue retinal neurons from apoptosis after ischemia, it is most desirable to have a neuroprotectant that directly targets apoptosis itself.
The key and final element in the apoptotic pathway is the processing and activation of caspases that dismantle the cell by cleaving various substrates including cytoskeletal proteins and repair enzymes. 12 In retinal ischemia, apoptosis can be initially detected in the ganglion cell layer (GCL) at 2 h post-ischemia, peaking at 9 h post-ischemia in the inner nuclear layer (INL). 13 In vivo studies conducted by Katai and Yoshimura 13 demonstrated upregulation of caspase 1 and 3 expression after retinal ischemia-reperfusion injury. Caspase 3 was highly expressed in INL, outer nuclear layer (ONL) photoreceptor cells and amacrine neurons while caspase 1 was more predominant in the ONL. 13, 14 Recently, inhibitors of apoptosis (IAPs) have gained much attention as potential tools for gene therapy because of their impressive ability to inhibit the final caspase cascade. Members of the mammalian IAP protein family may contain a caspase recruitment domain (CARD) that mediates oligomerization with CARD containing proteins, 15, 16 and/or a really interesting new gene (RING) zinc-finger domain which promotes protein degradation by ubiquitination. 15, 17 All IAPs contain at least one Baculovirus IAP Repeat (BIR) domain that allows direct binding to and inhibition of caspases. 15 XIAP is the most potent IAP. [18] [19] [20] It inhibits apoptosis by directly blocking the activity of caspases 3, 7 and 9 via its three N-terminal BIR domains. [18] [19] [20] In vivo studies have shown that XIAP overexpression in injured neuronal tissue retards cell death and protects tissue from being seriously compromised further. [20] [21] [22] [23] In keeping with the strong anti-apoptotic effect of XIAP, we report here that XIAP overexpression protected the retina from infarction due to transient ischemia induced by increasing intraocular pressure. Our results indicate that, in the presence of XIAP, retinal function was maintained up to 4 weeks post-ischemia. We show further that retinal structure, assessed by counting cells in the INL, measuring inner retinal thickness and counting axons in optic nerve cross-sections, was significantly maintained in the presence of XIAP. We propose that XIAP can act as a protective agent against retinal ischemic injury.
Results

XIAP expression
At 6 weeks after adeno-associated virus (AAV)-mediated gene delivery, retinal tissue was processed to assess XIAP expression levels by immunoblot analysis. Overexpression of exogeneous XIAP was detected in retinal tissue from eyes injected with AAV-XIAP in comparison to untreated, control eyes ( Figure 1 ). This indicated that cells transduced with AAV-XIAP synthesized significant levels of XIAP in the retina. Expression of GFP in retinal protein extracts was also verified by immunoblot analysis (not shown). GFP was detected in AAV-GFPtreated retinas while no GFP was detected in untreated, control eyes.
Electrophysiology
Ischemia was induced in the right eye in rats by increasing intraocular pressure and collapsing the central artery. Left eyes served as non-ischemic, untreated controls. Scotopic-photopic electroretinography (ERG) was performed bilaterally on rats in both the XIAP and GFP groups 24 h post-ischemia, and 4 weeks postischemia. ERG waveform morphologies of rat ischemic eyes were characteristic of those found in humans. A hyperpolarizing a-wave was present as expected, but there was no recovery of the b-wave above baseline levels in untreated, ischemic eyes. This is the classic negative ERG characteristic of central retinal artery occlusion. To assess b-wave amplitude preservation, the b-wave amplitude of the treated eye (OD) was divided by that of the contralateral, untreated eye (OS) to give a b-wave amplitude ratio (OD:OS). The closer the ratio was to 1.0, the better the preservation of the b-wave amplitude. At 24 h post-ischemia, we observed that the XIAP-treated eyes possessed b-wave amplitude ratios that were closer to 1.0 in comparison to the GFP-treated eyes (Figure 2a ). The two groups were significantly different for all except the lowest intensities. At 4 weeks post-ischemia, both groups showed better, but not full recovery. The b-wave amplitude ratio in the XIAPtreated group was significantly higher than that of the GFP-treated group at the two highest light intensities (Figure 2b ).
Histological analysis
The structural effects of ischemia were analyzed on images of retinas that had been stained with hematoxylin and eosin. Figure 3 shows representative retinal morphologies examined 24 h and 4 weeks post-ischemia. At 24 h post-ischemia, there was no evident effect in XIAP-treated ischemic retinas in comparison to nonischemic, untreated retinas (Figure 3a and b) . In GFPtreated ischemic retinas, the entire retina was reduced in thickness in comparison to non-ischemic, untreated retinas by 24 h (Figure 3c ). Inner retinal loss in GFPtreated retinas at 4 weeks post-ischemia was more pronounced with greater disorganization of cells and thinning of retinal layers (Figure 3f ). Retinas treated with XIAP showed better preservation even at 4 weeks postischemia (Figure 3e ). 
Optic nerve analysis
The effect of cell loss from the inner retina was analyzed in cross-sections of optic nerves. A marked reduction in size and a change in shape were detected in the GFP-treated samples relative to the untreated and XIAP-treated samples (Figure 6a -c). We observed many dying axons in GFP-treated samples, characterized by an unhealthy myelin sheath (Figure 6c ; red arrow). In addition, some dying axons exhibited moderate to heavy discolouration. We also observed greater infiltration of Neuronal counts of the INL in retinas treated with XIAP or GFP at T ¼ 0, 24 h and 4 weeks post-ischemia. Cells were counted from hematoxylin and eosin-stained cryosections taken through the para-papillary (a) and mid-periphery (b) region of retinas. Cell counts were pooled for untreated control retina. XIAP-treated retinas retained significantly more cells up to 4 weeks post-ischemia in the para-papillary region. *Represents Po0.05 using MannWhitney test.
XIAP-mediated neuroprotection in retinal ischemia J Renwick et al glial tissue in GFP-treated samples compared to XIAPtreated samples (Figure 6b and c; black arrows). There was no significant difference in the number of axons in XIAP-treated eyes compared to non-ischemic, untreated controls ( Figure 6d ). However, a significant reduction in axonal counts was observed in GFP-treated eyes compared to controls (Figure 6d ; P ¼ 0.001).
TUNEL analysis
To verify that cell loss was due to apoptosis, TdT-dUTP terminal nick end labeling (TUNEL) analysis was performed. At 24 h post-ischemia, more TUNEL-positive staining was noted within the INL and GCL cells in GFPtreated retinas (Figure 7b ) compared to the XIAP-treated group (Figure 7a ) in both the para-papillary and midperipheral regions. There was a significant decrease in the percentage of TUNEL-positive cells in the parapapillary region of the INL in XIAP-treated retinas compared to the GFP-treated retinas (Figure 7c ; Po0.05).
Discussion
In this study, we observed a neuroprotective effect against induced retinal ischemia by the intravitreal administration of XIAP. Using electrophysiological criteria, the preservation of the b-wave amplitude due to XIAP-treatment over a 4-week period suggests that XIAP is rescuing the ischemic neural retina from complete infarction. Complimenting the maintenance of retinal function in the presence of XIAP is the histological finding that XIAP-treated retinas are significantly protected on a structural level in comparison to retinas treated with GFP. In keeping with previous studies indicating cell loss due to ischemia occurs in part by apoptosis, we observed reduced TUNEL-positive cells in XIAP-treated retinas. These observations indicate XIAPmediated gene therapy protects cells against retinal ischemia by tempering the apoptotic pathway.
A similar neuroprotective effect of XIAP has been observed in a number of animal models of neuronal degeneration including transient forebrain ischemia produced by four-vessel occlusion, 23 the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) model of Parkinson's disease, 21 a chronic ocular hypertensive model of rat glaucoma, 20 and a MNU-induced model of retinal degeneration. 22, 24 In these studies, overexpression of XIAP prevented degeneration in a number of neuronal cell-types including CA1 neurons, dopaminergic substantia nigra pars compacta (SNpc) neurons, optic nerve axons and photoreceptor cells. In the transient forebrain ischemia model, XIAP overexpression promoted neuroprotection by blocking the apoptotic pathway via inhibition of caspase-3 production. 23 Our present results are consistent with findings in these earlier studies and extend our understanding to particular retinal layers. 
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Similar to previous studies, the effects of retinal ischemia are predominantly found in the inner retina in GFP-treated eyes. 25 This likely occurs for two reasons: (1) the GCL and INL draw their blood supply from the ophthalmic (retinal) artery, whereas the ONL derives its blood supply from the ciliary arteries, 1, 26 and (2) the inner retina has a higher oxygen demand than the outer retina. 26 At 24 h post-ischemia, the b-wave amplitude ratios of the XIAP-treated group are significantly higher than the GFP-treated group across all but the lowest intensities. This trend continues at 4 weeks post-ischemia although the differences are only significant at the highest intensities. Some recovery of function is present at 4 weeks post-ischemia for GFP-treated retinas. This could be an adaptive response on the part of the ischemic retina whereby some INL cells compensate for affected cells by way of synaptic plasticity. In studies on larval salamanders, Gross et al. 27 found that certain subsets of ganglion cells were differentially sensitive to hypoxia with subsets compensating for the affected ganglion cells. Studies have also shown that certain INL cell types are more susceptible to ischemia than others. 14, 28, 29 In our experiments, synaptic plasticity may be sufficient to allow a limited 'regaining' of function at 4 weeks postischemia in GFP-treated retinas.
Both a direct measure of neuronal loss by counting cells in the INL and axons in the optic nerve and an indirect method of measuring retinal thickness demonstrate a neuroprotective effect of XIAP. The effect is greatest at 24 h post-ischemia, but persists at 4 weeks after ischemia. INL cell counts in retinal cross-sections of the XIAP-injected eyes are significantly higher than GFP controls at 24 h in both the para-papillary region and the mid-periphery. A significant number of INL cells are lost in GFP-treated retinas within 24 h of the ischemic event with no evident structural recovery by 4 weeks. In sharp contrast, XIAP-treated retinas exhibit a minimal loss of the INL by 4 weeks post-ischemia. Similarly, retinal thickness is preserved in XIAP-treated retinas. The INL is significantly thicker in XIAP-treated retinas in both the para-papillary region and the mid-periphery in comparison to GFP controls. The IPL-ILM thickness appears to be more affected by the ischemic event suggesting some degeneration of the INL cell and ganglion cell axons. 30 Previous studies have shown that horizontal and Muller cells are resistant or only mildly susceptible to transient ischemia, while the amacrine and ganglion cells are more susceptible. 14, 28, 29 Both the GFP and XIAP-treated retinas have diminished IPL-ILM thickness but XIAP offers significantly more protection up to 4 weeks postischemia.
Preservation of optic nerve axonal counts in XIAPtreated eyes is further evidence of ganglion cell preservation in the inner retina. A significant loss of axons in the optic nerve in GFP-treated retinas correlates with the observed loss of thickness in the IPL-ILM layer. Furthermore, we have observed more glial tissue in GFP-treated samples. Infiltration of glial tissue is considered a hallmark following ischemia-induced injury to the inner retina and optic nerve. [31] [32] [33] These data are very encouraging when considering we used a single intravitreal injection of AAV-XIAP and yet delivered significant neuroprotection to the retina. Furthermore, we observed significant preservation of not only the ganglion cells where our constructs are primarily expressed but also the INL and IPL. Clearly, the consistency of inner retinal preservation in 25 independent, intravitreally XIAP-injected rat retinas indicates that our observations are not a result of inadvertent intraretinal injection. Neuroprotection of the ganglion cells by XIAP also results in preservation of the inner retina, since INL neurons synapse with ganglion cells and will consequently be affected by their survival.
XIAP exerts its neuroprotective effect on neurons by inhibiting apoptosis. 19 In the current study, we show that XIAP has the potential to protect the inner retina both structurally and functionally. The persistence of these effects at 4 weeks following ischemia suggests XIAP confers permanent protection. Thus, XIAP-mediated gene therapy holds promise as a therapy in the clinic. It is important to note, however, that gene therapy in retinal ischemia using AAV vectors provides valuable information on the efficacy of XIAP as a neuroprotective agent, but will not be immediately applicable to acute human disease. Arterial occlusion in the retina occurs suddenly, often without prior warning, and requires rapid treatment. AAV vectors would be ineffective in a therapeutic strategy unless there was a predisposition to retinal ischemia such as occurs in diabetic retinopathy or there were warning signs of an impending retinal ischemic event. Different strategies for the rapid delivery or upregulation of XIAP will need to be explored before XIAP therapy can become clinically applicable. Nevertheless, our data constitute important preclinical proof of principle for XIAP neuroprotection in the ischemic eye.
Materials and methods
Animals
Male Sprague-Dawley rats (Charles River) were obtained at 75-100 g and maintained on a 12 h light-12 h dark cycle. All procedures adhered to the ARVO statement for the Use of Animals in Ophthalmic and Vision Research and were also approved by the University of Ottawa Animal Care facility. Rats were divided into two major groups: those that would receive the gene therapy (XIAP; N ¼ 25 rats) and those that would receive the control (GFP; N ¼ 22 rats). Within each group, animals were sampled at T ¼ 0, 24 h and 4 weeks post-ischemia.
Adeno-associated virus
A cDNA construct, coding for the full open-reading frame of XIAP with a hemagglutinin (HA) tag at the N-terminus, was inserted into a pTR vector 34 under the control of the chicken b-actin promoter. A GFP construct was generated in the same way for use as a negative control. DNA sequence analysis confirmed orientation and reading frame.
Serotype 2 AAV particles were produced in the presence of a mini-Ad helper plasmid pDG38, by double transfection of 293 cells and purified by iodixanol gradient followed by heparin-sepharose agarose column chromatography (Amersham Biosciences, Piscataway, NJ, USA). Vector genome titers were calculated by quantitative competitive PCR. Contaminating helper adenovirus and wild-type AAV, assayed by serial dilution cytopathic effect or infectious center assay, respectively, were below detection levels. The AAV-XIAP XIAP-mediated neuroprotection in retinal ischemia J Renwick et al virus was prepared at 4 Â 10 13 vector genome containing particles/ml; the AAV-GFP virus was prepared at 2 Â 10 13 vector genome containing particles/ml.
Intravitreal injections
Intravitreal injections were performed as described by Timmers et al. 35 with the following modification: the virus was delivered to the ventral nasal quadrant of the vitreous of the right eye. Following anesthetization using halothane in O 2 , eyes were dilated using 1% tropicamide (Mydriacyl; Alcon Canada, Mississauga, ON, Canada) and 2.5% phenylephrine hydrochloride (Mydfrin; Alcon). When eyes were fully dilated, the topical anaesthetic Alcaine (Alcon) was applied to the right eye. Maxitrol (Alcon), an ophthalmic, anti-inflammatory antibiotic ointment, was administered to the contralateral eye. The cornea of the right eye was punctured with a 30-gauge needle. The virus was delivered using a bluntend 33-gauge needle attached to a Hamilton syringe. The needle was manoeuvred through the corneal puncture, around the lens displacing it medially, and 2 ml of virus (with fluorescein tracer) was delivered in the ventral nasal quadrant of the vitreous. The needle was withdrawn and Maxitrol was applied to the cornea.
Retinal ischemia
At 6 weeks after intravitreal viral delivery, ischemia was induced in the right injected eye. Animals were anaesthetized with halothane in O 2 . Eyes were dilated with 1% tropicamide (Alcon) and 2.5% phenylephrine hydrochloride (Alcon). Alcaine (Alcon) was applied to the cornea. The anterior chamber of the eye was cannulated with a 30-gauge needle connected to a saline reservoir and a manometer to measure pressure. The intraocular pressure was raised to 110 mmHg72 for 60 min by elevating the saline reservoir. Ischemia was confirmed by loss of redness in vasculature of the iris and in the posterior chamber of the eye. The right eye was kept hydrated using Gonak (Alcon). After 1 h of ischemia, the pressure in the eye was allowed to return to normal and the needle was removed.
Scotopic-photopic ERG
Full-field scotopic-photopic ERG was conducted on rats that had been dark-adapted overnight. Under safelight conditions, rats were given an anesthetic cocktail consisting of 80 mg/kg ketamine and 6.4 mg/kg xylazine. Pupils were dilated and the corneal surface was anaesthetized, as above. A platinum electrode was applied to the center of the cornea of each eye. Ground and reference electrodes were placed in the tail and mouth, respectively. Eyes were hydrated and contact between the electrode and cornea was optimized using Gonak (Alcon). The rat's head was positioned beneath a Ganzfeld apparatus (Espion system, Diagnosys, Littleton Co.). Pulse flashes of white light, 4 ms in duration, were generated at a frequency of 1 Hz. Responses from the retinal cells were tested at 10 different light intensities: 0.0025, 0.006, 0.016, 0.04, 0.1, 0.25, 0.63, 4, 10, and 25 Candela seconds per meter squared (Cd . s/m 2 ). ERGs were recorded at 24 h, 2 weeks and 4 weeks postischemia. Five representative ERG traces were obtained and averaged for each luminance step. The b-wave amplitude of the treated eye was divided by that of the non-ischemic, untreated eye to give a b-wave amplitude ratio (OD:OS). The data were reported as mean7s.e.m. with Po0.05 using Student's T-test considered statistically significant.
Tissue sampling
Prior to removal, eyes were scored to allow orientation before embedding. A small hole was made in the cornea to allow penetration of the fixative, and eyes were placed in labeled cryovials with 4% PFA. Eyes were fixed for 1 h. Lenses were removed and eyes were incubated in 30% sucrose overnight, followed by incubation in 50:50 OCT: 30% sucrose for 2-3 h. Eyes were oriented in plastic molds based on the placement of the score marks, and carefully lowered onto a Petri dish floating on liquid nitrogen. Once completely frozen, samples were stored at À801C. Samples were sectioned at 10 mm on a Shandon Electronic Cryotome, air-dried for 2 h and stored at À201C with desiccant.
Western blot analysis
Retinal tissue from three eyes was homogenized in RIPA Buffer (50 mM Tris HCl at pH 7.4, 150 mM NaCl, 1 mM EDTA, 1 mM NaF, 1 mM vanadate, 1% Noniodet P-40, 0.25% Na-deoxycholate, 1 Â Leupeptin, 1 Â Aprotinin, 1 Â PMSF). Homogenates were rocked for 1 h at 41C, and then centrifuged at 13 000 r.p.m. for 15 min at 41C. The supernatant was collected and protein concentration was determined using the DC assay (BioRad Laboratories). Samples (40 mg) were resolved by discontinuous SDSpolyacrylamide gel electrophoresis and transferred to PVDF membrane (Millipore). The membrane was blocked overnight in 5% dry milk and then incubated with rabbit anti-GFP IgG at 1:2000 (Molecular Probes), or rabbit anti-XIAP at 1:2000 for 1 h. Blots were hybridized with HRP-conjugated anti-rabbit IgG (Jackson ImmunoResearch Laboratories) and proteins were detected using the ECL detection kit (Amersham Biosciences).
Histological analysis
Morphological evaluations were performed on 10 mm sections stained with hematoxylin and eosin (H&E). Images of the retinas were obtained at approximately 440 mm (para-papillary region) and 1320 mm (mid-periphery region) from the optic nerve head at 40 Â magnification using a Zeiss Axioskop microscope with a Zeiss AxioCam HRc camera. INL cell numbers were determined by four independent masked observers. The thickness of the INL and the IPL-ILM were measured in five quadrants for each retinal image. The data were pooled for all non-ischemic, untreated eyes. The mean7s.e.m. was reported, with Po0.05 using MannWhitney test considered statistically significant.
Optic nerve analysis
Optic nerve stalks from animals killed 4 weeks postischemia were fixed in 4% PFA for 4 h, rinsed in 1 Â PBS and treated with osmium tetraoxide. Stalks were embedded in Epon and sectioned at 0.5 mm. The sections were stained with 1% Toluidene Blue and cover-slipped. Sections were photographed at 63 Â magnification using the Zeiss Axioskop light microscope and Zeiss AxioCam HRc camera. Axonal counts were taken from digitized images using Northern Eclipse software (Empix Inc., Mississauga, Canada). Approximately 35% of the total optic nerve area was counted and results were extra-XIAP-mediated neuroprotection in retinal ischemia J Renwick et al polated to the entire optic nerve area. The data were reported as mean7s.e.m. with Po0.05, using MannWhitney test, deemed statistically significant.
TUNEL
TUNEL analysis was conducted on eye sections at 24 h post-ischemia. Slides (10 mm thick sections) were dipped into distilled water and air-dried for 2 min. TUNEL-positive cells were detected using the Apoptag Peroxidase in situ Apoptosis Detection Kit (Chemicon) as recommended. The number of TUNEL-positive cells was counted for each sample to obtain a percentage of TUNEL positivity to the total number of nuclear-stained cells.
Statistical analysis
The standard error of the mean (s.e.m.) was obtained for all averages. Student's T-test was used to compare electrophysiology and TUNEL results. The Mann-Whitney test was used to compare cell counts, retinal thickness and optic nerve axonal counts between experimental and control groups. Values less than 0.05 were considered statistically significant.
